Nelivaptan Explained

Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

See also

Notes and References

  1. World Health Organization . World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 . WHO Drug Information . 21 . 4 . 341 . 2007 .
  2. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P . Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders . Proc. Natl. Acad. Sci. U.S.A. . 99 . 9 . 6370–5 . 2002 . 11959912 . 10.1073/pnas.092012099 . 122955 . 2002PNAS...99.6370G . free .
  3. Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A . An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders . CNS Drug Reviews . 11 . 1 . 53–68 . 2005 . 15867952 . 10.1111/j.1527-3458.2005.tb00035.x. 6741711 .
  4. Web site: Second-quarter 2008 results . 2008-07-31 . Press Release . Sanofi-Aventis . https://web.archive.org/web/20081206172930/http://en.sanofi-aventis.com/binaries/20080731_results2008_Q2_CP_EN_tcm28-20271.pdf . 2008-12-06 . It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist). . 2009-06-10 . dead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nelivaptan".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.